Quantcast

Latest Valeant Pharmaceuticals Stories

2014-05-12 16:29:38

LAVAL, Quebec, May 12, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that certain of its subsidiaries have entered into settlement agreements with affiliates of Actavis plc related to Actavis' generic versions of Acanya® Gel, 1.2%/2.5%, and Tiazac ® XC. Valeant's subsidiaries, Dow Pharmaceuticals Sciences, Inc. and Valeant Pharmaceuticals North America LLC, and Actavis' subsidiary, Watson Laboratories, Inc., entered into...

2014-05-12 08:31:42

DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya(® )(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya(®) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant...

2014-05-08 08:31:18

LAVAL, Quebec, May 8, 2014 /PRNewswire/ -- -- 2014 First Quarter Total Revenue $1.9 billion; an increase of 77% over the prior year -- Exceeded our expectations -- Launched 11 new products in the U.S. -- Positive organic growth in the U.S. despite the generic impact of Zovirax and RAM coupled with the new generic entry for Vanos -- Bausch + Lomb double-digit organic growth trend continued -- 2014 First Quarter GAAP EPS loss...

2014-05-01 16:33:44

LAVAL, Quebec, May 1, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders. The meeting and webcast will be held on Tuesday, May 20, 2014, at 9:00 a.m. ET at the International Headquarters, Laval Office: 2150 Saint Elzear Blvd. West, Laval Quebec, Canada H7L 4A8. Only shareholders of record at the close of business on the record date will be...

2014-04-28 16:31:44

Seasoned life sciences corporate development executive joins Endo to lead global acquisitions and integrations, to drive continued growth strategy DUBLIN, April 28, 2014 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today the appointment of Hemanth J. Varghese, Ph.D., CFA, as executive vice president of corporate development and strategy, effective immediately. Dr. Varghese brings to Endo a successful track record in corporate development and general...

2014-04-28 12:30:28

DUBLIN, Apr. 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/b9jbpq/global) has announced the addition of the "Global Hypertension Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking...

2014-04-24 16:29:08

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) and Pershing Square Capital Management L.P. ("Pershing Square") today announced that they have released the webcast replay and accompanying presentations from the April 22, 2014 investor meeting featuring Valeant Chairman and Chief Executive Officer, J. Michael Pearson and Pershing Square Chief Executive Officer, William A. Ackman, outlining Valeant's proposed acquisition of...

2014-04-24 12:30:07

LAVAL, Quebec, April 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, May 8, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2014 first quarter. The dial-in number to participate on this call is (877) 876-8393, confirmation code 28376511. International callers should dial (973) 200-3961, confirmation...

2014-04-23 08:31:50

LAVAL, Quebec, April 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today its nominees to stand for election to the Board of Directors at its annual meeting of shareholders on May 20, 2014. Given Valeant's increased size as a company and its ability to look at a broader set of business development opportunities, three of our Directors, who have full-time jobs looking at healthcare investment opportunities, feel that continued...

2014-04-22 08:32:39

This Offer Represents a Substantial Premium to Allergan's Unaffected Stock Price of $116.63 on April 10, 2014, the Day Before Pershing Square Crossed the 5% Schedule 13D Ownership Level and Commenced its Rapid Accumulation Program LAVAL, Quebec, April 22, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) announced today that it has submitted a merger proposal to the Board of Directors of Allergan, Inc. (NYSE: AGN) under which each Allergan...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'